Female chemist at work in laboratory.
Our Work

Latham & Watkins Advises IDEAYA Biosciences in Public Offering

November 1, 2023
Firm represents the precision medicine focused oncology company in the offering.

IDEAYA Biosciences, Inc. (Nasdaq:IDYA) has announced the closing of its underwritten public offering of 5,797,872 shares of its common stock at a public offering price of US$23.50 per share, before underwriting discounts and commissions, and pre-funded warrants to purchase 319,150 shares of common stock at a public offering price of US$23.4999 per pre-funded warrant, before underwriting discounts and commissions. This includes the exercise in full by the underwriters of their option to purchase up to an additional 797,872 shares of common stock in the offering. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by IDEAYA, were approximately US$143.8 million.

Latham & Watkins advised IDEAYA Biosciences in the transaction with a corporate deal team led by Bay Area partners Mark Roeder and John Williams, with Orange County associates Eric Hanzich, Tiana Baghdikian, Caitlin Nguyen, and Amy Lutfi. Advice was also provided on intellectual property and technology transactions by Bay Area/San Diego partner Christopher Hazuka, on employee benefits and compensation matters by Bay Area partner James Metz; on tax matters by Bay Area partner Grace M. Lee, with associate Rasha Suleiman; and on FDA regulatory matters by Washington, D.C. partner John Manthei, Bay Area partner Betty Pang and Washington, D.C./San Diego counsel Amy Speros, with associate Kiera Murphy.